1. Market Research
  2. > ConjuGon, Inc. - Product Pipeline Review - 2013

ConjuGon, Inc. - Product Pipeline Review - 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 18 pages

ConjuGon, Inc. - Product Pipeline Review - 2013


Global Market Direct’s pharmaceuticals report, “ConjuGon, Inc. - Product Pipeline Review - 2013” provides data on the ConjuGon, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ConjuGon, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ConjuGon, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


- ConjuGon, Inc. - Brief ConjuGon, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ConjuGon, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ConjuGon, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ConjuGon, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ConjuGon, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ConjuGon, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ConjuGon, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ConjuGon, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ConjuGon, Inc. and identify potential opportunities in those areas.

Table Of Contents

ConjuGon, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
ConjuGon, Inc. Snapshot 4
ConjuGon, Inc. Overview 4
Key Information 4
Key Facts 4
ConjuGon, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
ConjuGon, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
ConjuGon, Inc. - Pipeline Products Glance 9
ConjuGon, Inc. Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
ConjuGon, Inc. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
ConjuGon, Inc. - Drug Profiles 12
B-4474 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
C-1205 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Drug For Gram Positive Wound Infections 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
ConjuGon, Inc. - Pipeline Analysis 15
ConjuGon, Inc. - Pipeline Products by Therapeutic Class 15
ConjuGon, Inc. - Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
Coverage 17
Secondary Research 17
Primary Research 17
Expert Panel Validation 17
Contact Us 18
Disclaimer 18

List of Tables

ConjuGon, Inc., Key Information 4
ConjuGon, Inc., Key Facts 4
ConjuGon, Inc. - Pipeline by Indication, 2013 6
ConjuGon, Inc. - Pipeline by Stage of Development, 2013 7
ConjuGon, Inc. - Monotherapy Products in Pipeline, 2013 8
ConjuGon, Inc. - Phase I, 2013 9
ConjuGon, Inc. - Preclinical, 2013 10
ConjuGon, Inc. - Discovery, 2013 11
ConjuGon, Inc. - Pipeline By Therapeutic Class, 2013 15

List of Figures

ConjuGon, Inc. - Pipeline by Indication, 2013 6
ConjuGon, Inc. - Pipeline by Stage of Development, 2013 7
ConjuGon, Inc. - Monotherapy Products in Pipeline, 2013 8
ConjuGon, Inc. - Pipeline By Therapeutic Class, 2013 15

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.